Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 14/09/2015 A man and two young women standing next to a bioreactor and smiling into the camera.

    A membrane for protein factories of the future

    The cellular protein machinery is a marvel of nature and produces umpteen different proteins. Most of these proteins pass through a stack of membrane-enclosed discs, known as the Golgi apparatus, a miniature reaction chamber where the finishing touch is progressively added to the proteins. Rudolf Hausmann, professor and head of the Department of Bioprocess Engineering at the University of Hohenheim, is developing membranes based on the Golgi…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-membrane-for-protein-factories-of-the-future
  • Article - 03/09/2015 Coloured photo of Patrick Müller touching a shelf with a fish tank with zebrafish.

    Pattern formation: How undifferentiated cell clusters develop orderly structures

    Dr. Patrick Müller explores cellular signalling pathways that turn undifferentiated cell clusters into orderly structures as embryos develop. Supported by an ERC grant, the Max Planck researcher from Tübingen uses a broad range of methods from the fields of genetics, biophysics, mathematics and the computer sciences for his investigations. Regenerative medicine is one field that particularly stands to benefit from Müller’s findings.

    https://www.gesundheitsindustrie-bw.de/en/article/news/pattern-formation-how-undifferentiated-cell-clusters-develop-orderly-structures
  • Press release - 26/08/2015 Immatics Logo

    Immatics Biotechnologies GmbH - new alliances and launch of Immatics US, Inc.

    MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology. Furthermore Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-biotechnologies-gmbh-new-alliances-and-launch-of-immatics-us-inc
  • Epigenetics - 10/08/2015 jeltsch2.jpg

    Reading domains detect and identify histone modifications

    Prof. Dr. Albert Jeltsch from the Institute of Biochemistry at the University of Stuttgart and his team of researchers have now presented an alternative method to detect and identify changes in the post-translational modifications of histones. They envisage that their new method, which uses parts of natural proteins, so-called reading domains, will make such tests cheaper and simpler, and experimental data more reliable.

    https://www.gesundheitsindustrie-bw.de/en/article/news/reading-domains-detect-and-identify-histone-modifications
  • Article - 20/07/2015 Fluorescence microscope image of cells. The photo on the left shows a stationary cell layer with red circles and red boundaries; the photo on the right shows red circles against a blurred green background.

    How cells communicate with each other

    The ability of cells to move around as a cohesive group and communicate with each other plays a major role in many vital processes, including wound healing and embryo development. One cell becomes a lead cell and determines the direction that follower cells take. Researchers led by biophysicist Joachim Spatz from the Max Planck Institute for Intelligent Systems in Stuttgart have successfully decoded the collective movement of cells in the body.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-cells-communicate-with-each-other
  • Article - 06/07/2015 site_image-2.jpg

    Using mosses to produce medicines

    Human disease can be treated with substances from traditional medicinal plants or with molecular pharming products. Molecular pharming uses genetic engineering techniques to insert genes into plants or animals that would otherwise not express these genes. These transgenics can then be used to produce therapeutic proteins such as antibodies. Dr. Eva Decker from the University of Freiburg and her team have now successfully produced a key protein of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/using-mosses-to-produce-medicines
  • Article - 29/06/2015 15921_de.jpg

    The transition from acute to chronic pain

    Prof. Dr. Rohini Kuner and fellow scientists from Heidelberg have shown that a protein that inhibits an enzyme produced by immune cells protects nerve cells from chronic hypersensitivity to neuropathic pain. Kuner is also the spokesperson of a new collaborative research centre in Heidelberg that is receiving funding from the German Research Foundation totalling over 12 million euros. The centre is seeking to find the reasons why acute pain…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-transition-from-acute-to-chronic-pain
  • Article - 22/06/2015 Schematic showing how pharmaceutical substances travel directly from the nose to the brain by way of the olfactory nerve. From the olfactory mucosa, the substances travel up through the ethmoid bone and from there to the olfactory bulb where the fascicles of olfactory nerve end. <br />

    Through the nose directly into the brain: Biberach researchers are working on a novel way to apply pharmaceuticals

    The blood-brain barrier prevents most drugs, and large biologics in particular, from entering the brain. This physiological barrier impairs the study of central nervous system (CNS) diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis as well as the development of drugs. However, there is a hidden side entrance to the brain, which means that there is a way to circumvent this barrier.

    https://www.gesundheitsindustrie-bw.de/en/article/news/through-the-nose-directly-into-the-brain-biberach-researchers-are-working-on-a-novel-way-to-apply-pharmaceuticals
  • Article - 15/06/2015 Schematic presentation of molecular diagnostic procedures and bioinformatic analyses used for cancer patients.

    Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients

    Since January 2015, Tübingen has been home to a Centre for Personalised Medicine (ZPM). Twenty-three institutes and hospitals have joined forces to improve diagnosis of disease and develop individualised treatments for patients with a variety of diseases. In parallel, the centre also develops new diagnostic strategies. This means, for example, that data derived from the analysis of the entire genetic material of cells, proteins and metabolic…

    https://www.gesundheitsindustrie-bw.de/en/article/news/centre-for-personalised-medicine-in-tuebingen-developing-tailor-made-treatments-for-patients
  • Article - 08/06/2015 Schematic representation showing how the combination of two fragments (kidney-shaped green and orange, top right and left) makes it possible to design proteins with new functions (bottom, horseshoe-shaped, in this case by binding of an irregularly shaped, grey molecule that is not bound by the original proteins.

    New construction kit for designing new proteins

    Protein building blocks with well-defined properties that can be assembled into new molecules with desired structures and functions are highly sought after in biotechnology and medicine. Birte Höcker, a biologist at the Max Planck Institute for Developmental Biology in Tübingen, is currently working on this in a project she calls “Protein Lego”.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-construction-kit-for-designing-new-proteins
  • Article - 01/06/2015 Prof. Dr. Elke Deuerling and Dr. Martin Gamerdinger in the laboratory.<br /> <br />

    A protein complex that maintains order in the cell

    Researchers believe that the defective transport of proteins can be linked with diseases such as Alzheimer’s. Prof. Dr. Elke Deuerling and Dr. Martin Gamerdinger, molecular biologists from the University of Konstanz, have now discovered what is necessary to prevent erroneous protein transport.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-protein-complex-that-maintains-order-in-the-cell
  • Article - 26/05/2015 The photo shows two scientists looking into the camera.

    Novel effect of B-Raf inhibitors against bowel cancer discovered

    Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease in men and women in Germany. A particularly aggressive form occurs when a mutation is present in the proto-oncogene BRAF. As part of the Collaborative Research Centre 850 at the Institute of Molecular Medicine and Cell Research at the University of Freiburg, Dr. Ricarda Herr and Dr. Tilman Brummer are trying to find out how a mutated BRAF gene…

    https://www.gesundheitsindustrie-bw.de/en/article/news/novel-effect-of-b-raf-inhibitors-against-bowel-cancer-discovered
  • Article - 11/05/2015 Microscopic image of MTSS1 expression.

    Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease

    Lung cancer is one of the most common malignant diseases and one of the leading causes of cancer-related deaths worldwide. 90% of all lung cancer cases in men and 80% in women are due to long-term exposure to tobacco smoke. In Germany, around 140 new cases are diagnosed every day, and 50,000 people die of lung cancer every year. PD Dr. Gian Kayser, senior consultant in the Department of Clinical Pathology at Freiburg University Medical Centre,…

    https://www.gesundheitsindustrie-bw.de/en/article/news/lung-cancer-mtss1-is-a-putative-marker-of-tumour-progression-and-metastatic-disease
  • Article - 04/05/2015 The photo shows Dr. Horlacher.

    “Persistence leads to success” - corporate development in the biotech sector

    For graduates with innovative business ideas, becoming independent entrepreneurs can be an interesting alternative to traditional career paths. This is exactly what Dr. Reinhold Horlacher thought 15 years ago. He had just been awarded his PhD from the University of Konstanz, and had a business idea that he decided to turn into reality by establishing a company called Trenzyme GmbH. In the following interview with BIOPRO, he describes his…

    https://www.gesundheitsindustrie-bw.de/en/article/news/persistence-leads-to-success-corporate-development-in-the-biotech-sector
  • Article - 27/04/2015 23122_de.jpg

    Newly discovered gene mutation favour obesity

    Professor Martin Wabitsch from Ulm University Hospital has been studying the genetic causes of obesity for quite some time. The discovery of another cause of this complex condition that has key clinical consequences was recently published in the renowned New England Journal of Medicine. Despite the internationally acknowledged success of this research and in contrast to the view of the World Health Organisation and scientific organisations, the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-gene-mutation-favour-obesity
  • Overview

    Basic research

    The latest articles, press releases and dossiers on basic research in Baden-Württemberg

    https://www.gesundheitsindustrie-bw.de/en/article/research
  • Article - 16/03/2015 22977_de.jpg

    Heike Brötz-Oesterhelt - searching for novel antibiotics in bacteria

    Microbial metabolic products can be used in the fight against dangerous pathogens such as multidrug-resistant bacteria. Since summer 2014, microbiologist Prof. Dr. Heike Brötz-Oesterhelt has been investigating the mechanisms of action of bacterial substances at the University of Tübingen with the aim of paving the way for new antibiotics. Interesting candidates have already been identified.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heike-broetz-oesterhelt-searching-for-novel-antibiotics-in-bacteria
  • Article - 16/03/2015 Microscopic image of liver tissue. The area in the centre of the image has an intense yellow-red colour.<br />

    The critical balance between liver fibrosis and liver regeneration

    When the liver has been damaged, a receptor protein of the hepatic stellate cells called endosialin controls the balance between liver repair and scar formation. A team of researchers from Heidelberg and Mannheim has shown that endosialin is a positive regulator of fibrogenesis and a negative regulator of hepatocyte proliferation. Endosialin therefore seems to be a promising therapeutic drug target in non-neoplastic settings.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-critical-balance-between-liver-fibrosis-and-liver-regeneration
  • Article - 09/03/2015 3D schematic showing how atovaquone fits into the mitochondrial cytochrome bc1 binding pocket

    Malaria: when an antimalarial drug is no longer fit for purpose

    Malaria can be treated with atovaquone a drug that inhibits a particular enzyme in Plasmodia. However the parasites are becoming increasingly resistant to the drug. Carola Hunte and Dominic Birth from the Institute for Biochemistry at the University of Freiburg have shown how atovaquone binds to the protein and what happens at the molecular level in resistant plasmodia. Their research provides an impetus for structure-based drug design aimed at…

    https://www.gesundheitsindustrie-bw.de/en/article/news/malaria-when-an-antimalarial-drug-is-no-longer-fit-for-purpose
  • Press release - 06/03/2015 07777_de.jpg

    The Bill & Melinda Gates Foundation invests €46 million in CureVac

    The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest €46 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA platform. In addition, CureVac’s…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-bill-melinda-gates-foundation-invests-46-million-in-curevac
  • Article - 02/03/2015 22850_de.jpg

    EU supports biophysicists from Ulm to elucidate the structure of chromatin

    Human DNA consists of three billion base pairs, which corresponds to a total length of approximately two metres. DNA must be compressed 200,000-fold in order to fit into the tiny nuclei of mammalian cells. The thread-like complex of DNA and proteins is called chromatin. Although chromatin has been widely studied, relatively little is yet known about the spatial and temporal organisation of chromatin in interphase cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/eu-supports-biophysicists-from-ulm-to-elucidate-the-structure-of-chromatin
  • Article - 23/02/2015 Photo of a young woman smiling into the camera.

    Miriam Erlacher: apoptosis research – balancing clinical work and research

    Programmed cell death plays an important role in embryonic development and has also been identified as the cause of a range of diseases. It also plays a key role in the development and survival of higher organisms. Its regulation is based on a sophisticated system of interacting antagonistic signals in a network that is still largely unknown. Disturbances in this delicate balance promote the development of diseases such as cancer. Dr. Miriam…

    https://www.gesundheitsindustrie-bw.de/en/article/news/miriam-erlacher-apoptosis-research-balancing-clinical-work-and-research
  • Article - 16/02/2015 Model of the protein complex.

    The cellular power station of the cholera pathogen – from the structure to new antibiotics

    The bacterium Vibrio cholerae causes cholera, a severe disease that affects up to 3.5 million people a year. A team of scientists from the universities of Freiburg, Hohenheim and Konstanz have now gained new insights into the way the bacterium produces energy. They have elucidated the structure and function of the bacterium’s energy-production machinery. The research results provide new insights into biochemical energy production and the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-cellular-power-station-of-the-cholera-pathogen-from-the-structure-to-new-antibiotics
  • Article - 16/02/2015 22810_de.jpg

    Therapeutic vaccines against brain tumours

    Therapeutic cancer vaccines have the potential to boost the immune system's ability to destroy tumour cells. Cancer researchers around the world are intensively studying the potential of this therapeutic concept and initial positive results have been obtained. Cancer researchers from Heidelberg have developed a vaccine that triggers an immune response against a protein that is mutated in brain cancer. The vaccine, which successfully arrested…

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-vaccines-against-brain-tumours

Page 8 / 34

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 34
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search